Trial Profile
Comparative study of the inhibitory effect on bone erosion progression with Denosumab treatment and conventional treatment in rheumatoid arthritis patients. An open label randomized controlled trial by HR-pQCT.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Dec 2022 Primary endpoint (Depth change from baseline of bone erosion by HR-pQCT measurement 6 months after starting administration.) has not been met according to Results published in the Arthritis Research and Therapy.
- 07 Dec 2022 Results (n=43) assessing the effects of denosumab on bone micro-architecture and other bone-related parameters using high-resolution peripheral quantitative computed tomography published in the Arthritis Research and Therapy
- 04 Jun 2022 Results of exploratory analysis comparing patients receiving conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) for treatment of RA, the effectiveness of combined use of csDMARD and denosumab vs csDMARD alone presented at the 23rd Annual Congress of the European League Against Rheumatism